The exacerbation of cutaneous psoriasis induced by anti - TNF therapy - case report
| Autor: | Elena Rezus, Madalina Ionela Chiriac, Anca Costache |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Exacerbation business.industry Materials Science (miscellaneous) Arthritis medicine.disease General Business Management and Accounting Inflammatory bowel disease Dermatology Industrial and Manufacturing Engineering Infliximab Rheumatoid arthritis Psoriasis Adalimumab medicine Tumor necrosis factor alpha Business and International Management skin and connective tissue diseases General Agricultural and Biological Sciences business medicine.drug |
| Zdroj: | Archive of Clinical Cases. :23-27 |
| ISSN: | 2360-6975 |
| DOI: | 10.22551/2014.01.0101.10006 |
| Popis: | The tumor necrosis factor (TNF) blockers are highly effective therapy for numerous autoimmune inflammatory diseases, including rheumatoid arthritis, psoriatic arthropathy (PsA), spondyloarthropathies, juvenile idiopathic arthritis and inflammatory bowel disease. Paradoxically, these agents can induce cutaneous and systemic autoimmune diseases; the most common are psoriasis skin lesions and systemic lupus erythematosus (SLE) induced by TNF blockers. We present the case of a 59 years-old female, diagnosed at 32 years with cutaneous psoriasis vulgaris and psoriatic arthropathy at 54 years-old. After treatment failure with conventional Disease-Modifying Antirheumatic Drugs (DMARDs), biologic therapy with infliximab was started. After 3 years of treatment, the patient suffers an exacerbation of skin lesions and worsening joint damage. We decided to stop the infliximab and initiate the therapy with another anti-TNF agent (adalimumab), with improvement of the skin lesions and joint manifestations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|